Pfizer's small molecule tafamidis approved for TTR amyloid cardiomyopathy

FDA approved two forms of Pfizer's tafamidis Monday well ahead of their PDUFA dates, making the therapies the first small molecules approved for the cardiomyopathy dominant form of transthyretin (TTR) amyloidosis in the U.S. The tafamidis products are indicated for the wild-type and hereditary forms of the

Read the full 472 word article

How to gain access

Continue reading with a
two-week free trial.